Literature DB >> 32835362

Making Fluorouracil "Sexy" Again.

Patrick M Boland1, Howard S Hochster1.   

Abstract

Entities:  

Year:  2021        PMID： 32835362      PMCID： PMC8023836          DOI： 10.1093/jnci/djaa125

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  10 in total

1.  Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Authors:  Bart A W Jacobs; Maarten J Deenen; Dick Pluim; J G Coen van Hasselt; Martin D Krähenbühl; Robin M J M van Geel; Niels de Vries; Hilde Rosing; Didier Meulendijks; Artur M Burylo; Annemieke Cats; Jos H Beijnen; Alwin D R Huitema; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

2.  Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.

Authors:  Olivier Capitain; Andreaa Asevoaia; Michele Boisdron-Celle; Anne-Lise Poirier; Alain Morel; Erick Gamelin
Journal:  Clin Colorectal Cancer       Date:  2012-06-09       Impact factor: 4.481

3.  DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

Authors:  L M Henricks; F L Opdam; J H Beijnen; A Cats; J H M Schellens
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

Review 4.  Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.

Authors:  R B Diasio
Journal:  Oncology (Williston Park)       Date:  2001-01       Impact factor: 2.990

5.  Influence of sex and age on fluorouracil clearance.

Authors:  G Milano; M C Etienne; E Cassuto-Viguier; A Thyss; J Santini; M Frenay; N Renee; M Schneider; F Demard
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

6.  Population study of dihydropyrimidine dehydrogenase in cancer patients.

Authors:  M C Etienne; J L Lagrange; O Dassonville; R Fleming; A Thyss; N Renée; M Schneider; F Demard; G Milano
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

7.  Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

Authors:  Erick Gamelin; Remy Delva; Jacques Jacob; Yacine Merrouche; Jean Luc Raoul; Denis Pezet; Etienne Dorval; Gilles Piot; Alain Morel; Michele Boisdron-Celle
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

8.  The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Authors:  Winson Y Cheung; Qian Shi; Michael O'Connell; James Cassidy; Charles D Blanke; David J Kerr; Jeff Meyers; Eric Van Cutsem; Steven R Alberts; Greg Yothers; Daniel J Sargent
Journal:  Clin Colorectal Cancer       Date:  2013-06-27       Impact factor: 4.481

9.  Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study.

Authors:  F Mueller; B Büchel; D Köberle; S Schürch; B Pfister; St Krähenbühl; T K Froehlich; C R Largiader; M Joerger
Journal:  Cancer Chemother Pharmacol       Date:  2012-11-09       Impact factor: 3.333

10.  Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.

Authors:  Anna D Wagner; Axel Grothey; Thierry Andre; Jesse G Dixon; Norman Wolmark; Daniel G Haller; Carmen J Allegra; Aimery de Gramont; Eric VanCutsem; Steven R Alberts; Thomas J George; Michael J O'Connell; Christopher Twelves; Julien Taieb; Leonard B Saltz; Charles D Blanke; Edoardo Francini; Rachel Kerr; Greg Yothers; Jean F Seitz; Silvia Marsoni; Richard M Goldberg; Qian Shi
Journal:  J Natl Cancer Inst       Date:  2021-04-06       Impact factor: 13.506
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.